Concepedia

Deepak Bunger

DB

Statistics

Publications

5

Citations

78

H-Index

5

Active since

2017

Affiliations

Intas Pharmaceuticals (India)(Current)

All India Institute of Medical Sciences Bhubaneswar

Sparsh Hospital

Deepak Bunger is an author at Intas Pharmaceuticals (India) specializing in oncology, chemotherapy, and squamous cell carcinoma.

Publications per year

2017–2020

5

Publications

5

[Experts' Opinion] Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer

Senthil Rajappa, Ashish Joshi, Dinesh Chandra Doval et al. · Oncology Letters · 2018 · 23 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report

Rammohan Prasanna, Deepak Bunger, Mujtaba Khan · Molecular and Clinical Oncology · 2017 · 18 citations · Full text

Medicine, Oncology, Pharmacology +14

Management of primary squamous cell carcinoma of the pancreas with a nanosomal paclitaxel lipid suspension-based regimen: A case report

Saroj Kumar Das Majumdar, Dillip Kumar Muduly, Subhasis Mishra et al. · Molecular and Clinical Oncology · 2019 · 15 citations · Full text

Medicine, Oncology, Surgery +13

Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery

Sameer Gupta, Shashi Singh Pawar, Deepak Bunger · BMJ Case Reports · 2017 · 11 citations · Full text

Medicine, Oncology, Surgery +14

<p>Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study</p>

Sundaram Subramanian, Rammohan Prasanna, Ghanashyam Biswas et al. · Breast Cancer Targets and Therapy · 2020 · 11 citations · Full text

Medicine, Oncology, Pharmacology +16

1–5 of 5